title: Predictors of heart failure in patients with stable coronary artery disease: a PEACE study.
abstract: BACKGROUND
  Heart failure (HF) is a disease commonly associated with coronary artery disease. Most risk models for HF development have focused on patients with acute myocardial infarction. The Prevention of Events with Angiotensin-Converting Enzyme Inhibition population enabled the development of a risk model to predict HF in patients with stable coronary artery disease and preserved ejection fraction.
  
  
  RESULTS
  In the 8290, Prevention of Events with Angiotensin-Converting Enzyme Inhibition patients without preexisting HF, new-onset HF hospitalizations, and fatal HF were assessed over a median follow-up of 4.8 years. Covariates were evaluated and maintained in the Cox regression multivariable model using backward selection if P<0.05. A risk score was developed and converted to an integer-based scoring system. Among the Prevention of Events with Angiotensin-Converting Enzyme Inhibition population (age, 64+/-8; female, 18%; prior myocardial infarction, 55%), there were 268 cases of fatal and nonfatal HF. Twelve characteristics were associated with increased risk of HF along with several baseline medications, including older age, history of hypertension, and diabetes. Randomization to trandolapril independently reduced the risk of HF. There was no interaction between trandolapril treatment and other risk factors for HF. The risk score (range, 0 to 21) demonstrated excellent discriminatory power (c-statistic 0.80). Risk of HF ranged from 1.75% in patients with a risk score of 0% to 33% in patients with risk score >or=16.
  
  
  CONCLUSIONS
  Among patients with stable coronary artery disease and preserved ejection fraction, traditional and newer factors were independently associated with increased risk of HF. Trandolopril decreased the risk of HF in these patients with preserved ejection fraction.
authors.affiliation: Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass 02115, USA. eflewis@partners.org
authors.forename: Eldrin F
authors.initials: EF
authors.lastname: Lewis
authors.forename: Scott D
authors.initials: SD
authors.lastname: Solomon
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Jablonski
authors.forename: Madeline Murguia
authors.initials: MM
authors.lastname: Rice
authors.forename: Francesco
authors.initials: F
authors.lastname: Clemenza
authors.forename: Judith
authors.initials: J
authors.lastname: Hsia
authors.forename: Aldo P
authors.initials: AP
authors.lastname: Maggioni
authors.forename: Miguel
authors.initials: M
authors.lastname: Zabalgoitia
authors.forename: Thao
authors.initials: T
authors.lastname: Huynh
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Cuddy
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Gersh
authors.forename: Jean
authors.initials: J
authors.lastname: Rouleau
authors.forename: Eugene
authors.initials: E
authors.lastname: Braunwald
authors.forename: Marc A
authors.initials: MA
authors.lastname: Pfeffer
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C052035:trandolapril